Who are the top shareholders of the HCP Plastene?

The top shareholders of HCP Plastene include Aman Prakash Parekh with 16.86%, Bank of Baroda as the largest public shareholder at 4.8%, and individual investors holding a total of 12.81%. Additionally, foreign institutional investors hold a combined 0.07%, while mutual funds have a negligible stake.

The top shareholders of HCP Plastene include the promoters, with Aman Prakash Parekh holding the highest individual stake at 16.86%. Additionally, Bank of Baroda is the largest public shareholder, owning 4.8%. The company also has some institutional investment, with three foreign institutional investors (FIIs) holding a combined 0.07%, and mutual funds are represented by one scheme, which holds 0.0%. Individual investors collectively hold 12.81% of the shares.

What does HCP Plastene do?

HCP Plastene Bulkpack Ltd is a micro-cap company in the plastics packaging industry, reporting net sales of 122 Cr and a net profit of 5 Cr for the quarter ending March 2025. The company, rebranded in 2021, has a market cap of Rs 174 Cr and key financial metrics include a P/E of 18.00 and a debt-equity ratio of 3.18.

Overview:<BR>HCP Plastene Bulkpack Ltd operates in the plastics packaging industry and is classified as a micro-cap company.<BR><BR>History:<BR>The company was incorporated in 1984 under the name 'Gopala Polyplast Limited' and was rebranded to HCP Plastene Bulkpack Limited on September 22, 2021. The latest quarterly results reported net sales and profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>- Net Sales: 122 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 5 Cr (Quarterly Results - Mar 2025)<BR>- Market-cap: Rs 174 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 18.00<BR>- Industry P/E: 21<BR>- Dividend Yield: 0.00%<BR>- Debt-Equity: 3.18<BR>- Return on Equity: 15.93%<BR>- Price to Book: 2.79<BR><BR>Contact Details:<BR>Address: H B Jirawala House, Navbharat Soc Ushmanpura Ahmedabad Gujarat : 380013<BR>Email: hdpeaccounts@gopalapolyplast.com<BR>Website: http://www.gopalapolyplast.com

Who are the peers of the HCP Plastene?

HCP Plastene's peers include EPL Ltd, AGI Greenpac, Uflex, Polyplex Corpn, TCPL Packaging, Hind.Natl.Glass, Mitsu Chem Plast, Kaira Can, Hind.Tin Works, and Barflex Poly. HCP Plastene has good management risk and a 1-year return of 8.18%, lower than Polyplex Corpn's 66.57% but higher than Mitsu Chem Plast's -19.31%.

Peers: The peers of HCP Plastene are EPL Ltd, AGI Greenpac, Uflex, Polyplex Corpn, TCPL Packaging, Hind.Natl.Glass, Mitsu Chem Plast, Kaira Can, Hind.Tin Works, and Barflex Poly.<BR><BR>Quality Snapshot: Excellent management risk is observed at EPL Ltd, TCPL Packaging, Mitsu Chem Plast, and the rest. Average management risk is found at AGI Greenpac, Uflex, Kaira Can, Hind.Tin Works, and the rest. Good management risk is noted at HCP Plastene, while Hind.Natl.Glass does not qualify. Growth ratings show that good growth is at TCPL Packaging, while below average growth is seen at EPL Ltd, Uflex, Polyplex Corpn, HCP Plastene, Mitsu Chem Plast, Kaira Can, Hind.Tin Works, and the rest. Average growth is found at AGI Greenpac. Capital structure is excellent for Polyplex Corpn and Kaira Can, good for EPL Ltd and the rest, and average for AGI Greenpac, TCPL Packaging, Hind.Tin Works, and the rest, while HCP Plastene, Uflex, Mitsu Chem Plast, and the rest have below average capital structure.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Polyplex Corpn at 66.57%, while the lowest is Mitsu Chem Plast at -19.31%. HCP Plastene's 1-year return of 8.18% is lower than that of Polyplex Corpn but higher than Mitsu Chem Plast. Additionally, Hind.Natl.Glass, Mitsu Chem Plast, Kaira Can, Hind.Tin Works, and Barflex Poly have negative six-month returns.

What is the technical trend for HCP Plastene?

As of June 2, 2025, HCP Plastene's technical trend is mildly bearish, indicated by daily moving averages and monthly Bollinger Bands, despite some conflicting signals from weekly MACD and KST.

As of 2 June 2025, the technical trend for HCP Plastene has changed from sideways to mildly bearish. The daily moving averages indicate a mildly bearish stance, while the weekly MACD and KST are mildly bullish, suggesting some conflicting signals. The Bollinger Bands show a bearish trend on the monthly timeframe, which adds to the bearish outlook. Overall, the current technical stance is mildly bearish, driven primarily by the daily moving averages and the bearish signal from the monthly Bollinger Bands.

Who are in the management team of HCP Plastene?

As of March 2022, the management team of HCP Plastene includes Chairman Anil Goyel, Managing Director Prakash Parekh, and several independent directors: Meenu Maheshwari, Ashutosh Sushil Kumar Maheshvari, Sandeep M Shah, Deepti Sharma, and Judhisthir Behera, along with Company Secretary Krushang Shah.

As of March 2022, the management team of HCP Plastene includes the following individuals:<BR><BR>1. Anil Goyel - Chairman (Non-Executive)<BR>2. Prakash Parekh - Managing Director<BR>3. Meenu Maheshwari - Independent Director<BR>4. Ashutosh Sushil Kumar Maheshvari - Independent Director<BR>5. Sandeep M Shah - Independent Director<BR>6. Krushang Shah - Company Secretary & Compliance Officer<BR>7. Deepti Sharma - Independent Director<BR>8. Judhisthir Behera - Independent Director<BR><BR>This team comprises a mix of executive and independent directors, with Prakash Parekh serving as the Managing Director.

How big is HCP Plastene?

As of 24th July, HCP Plastene Bulkpack Ltd has a market capitalization of 226.00 Cr, with recent net sales of 463.43 Cr and a net profit of 9.49 Cr. The balance sheet for March 2024 shows shareholder's funds of 49.52 Cr and total assets of 206.70 Cr.

As of 24th July, HCP Plastene Bulkpack Ltd has a market capitalization of 226.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, HCP Plastene reported Net Sales of 463.43 Cr and a Net Profit of 9.49 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, showing Shareholder's Funds of 49.52 Cr and Total Assets of 206.70 Cr.

When is the next results date for HCP Plastene?

The next results date for HCP Plastene is 12 August 2025.

The next results date for HCP Plastene is scheduled for 12 August 2025.

Is HCP Plastene overvalued or undervalued?

As of October 28, 2025, HCP Plastene is considered undervalued with an attractive valuation grade, featuring a PE ratio of 14.48, an EV to EBITDA of 9.63, and a PEG ratio of 0.02, significantly outperforming peers like Garware Hi Tech and TCPL Packaging, and demonstrating a remarkable 3525.28% return over five years compared to the Sensex's 111.98%.

As of 28 October 2025, HCP Plastene's valuation grade has moved from fair to attractive, indicating a positive shift in its perceived value. The company is currently considered undervalued, especially when compared to its peers. Key ratios include a PE ratio of 14.48, an EV to EBITDA of 9.63, and a PEG ratio of 0.02, which suggests significant growth potential relative to its price.<BR><BR>In the peer comparison, HCP Plastene's PE ratio is notably lower than Garware Hi Tech's 24.96 and TCPL Packaging's 22.52, both of which are classified as expensive. Additionally, AGI Greenpac, which is very attractive, has a PE ratio of 15.19, further reinforcing HCP Plastene's undervaluation. Despite a recent decline in stock price, the long-term performance shows a remarkable 3525.28% return over five years, significantly outpacing the Sensex's 111.98% return in the same period, highlighting its potential for recovery and growth.

How has been the historical performance of HCP Plastene?

HCP Plastene's historical performance shows a recovery in net sales and profitability, with net sales rising to 463.44 Cr in Mar'25 from 294.56 Cr in Mar'24, and profit after tax increasing to 13.36 Cr. However, the company faces challenges with rising liabilities and negative cash flow from operating activities.

Answer:<BR>The historical performance of HCP Plastene shows significant fluctuations in key financial metrics over the years.<BR><BR>Breakdown:<BR>HCP Plastene's net sales experienced a notable increase from Mar'24 at 294.56 Cr to Mar'25 at 463.44 Cr, following a dip in Mar'23 at 351.56 Cr and a dramatic decline from Mar'22's 11,219.74 Cr. Total operating income mirrored this trend, rising to 463.44 Cr in Mar'25 from 294.56 Cr in Mar'24. The raw material cost also increased significantly, reaching 350.29 Cr in Mar'25 from 212.20 Cr in Mar'24, while total expenditure rose to 428.20 Cr in Mar'25. Operating profit (PBDIT) improved to 39.92 Cr in Mar'25, up from 19.23 Cr in Mar'24, indicating a recovery from the previous years' losses. Profit before tax turned positive at 18.01 Cr in Mar'25, compared to a mere 0.20 Cr in Mar'24, and profit after tax rose to 13.36 Cr from 0.31 Cr. The consolidated net profit for Mar'25 was 9.63 Cr, a recovery from losses in the previous years. Earnings per share (EPS) also improved to 9.03 in Mar'25 from -1.12 in Mar'24. However, the company faced challenges with total liabilities increasing to 206.70 Cr in Mar'24 from 175.25 Cr in Mar'23, and total debt rising to 157.90 Cr. Cash flow from operating activities remained negative at -18.00 Cr in Mar'24, though cash flow from financing activities was positive at 23.00 Cr. Overall, HCP Plastene's financial performance indicates a recovery trend in sales and profitability, despite ongoing challenges with liabilities and cash flow.

How has been the historical performance of HCP Plastene?

HCP Plastene's historical performance has shown significant fluctuations, with net sales peaking at 11,219.74 Cr in March 2022 before declining to 463.48 Cr by March 2025, while profitability metrics have improved, turning positive in March 2025 after previous losses. Despite ongoing challenges in cash flow from operations, the company has demonstrated signs of recovery in operating profit and net profit.

Answer:<BR>The historical performance of HCP Plastene shows significant fluctuations in key financial metrics over the years.<BR><BR>Breakdown:<BR>HCP Plastene's net sales have varied dramatically, peaking at 11,219.74 Cr in March 2022 before declining to 463.48 Cr in March 2025. The total operating income followed a similar trend, reaching its highest at 11,219.74 Cr in March 2022 and dropping to 463.48 Cr by March 2025. Raw material costs also surged, from 13.67 Cr in March 2021 to 350.34 Cr in March 2025. Operating profit, which was negative in March 2021, improved to 39.87 Cr by March 2025, indicating a recovery despite the decline in sales. Profit before tax turned positive at 17.96 Cr in March 2025, up from a loss of 315.92 Cr in March 2022. The profit after tax showed a similar recovery, reaching 13.31 Cr in March 2025 after being negative in previous years. The consolidated net profit also turned positive at 9.63 Cr in March 2025, compared to losses in the preceding years. On the balance sheet, total liabilities increased from 48.70 Cr in March 2021 to 206.70 Cr in March 2024, while total assets rose from 48.70 Cr to 206.70 Cr in the same period. Cash flow from operating activities remained negative, indicating ongoing challenges in generating cash from core operations. Overall, HCP Plastene has shown signs of recovery in profitability metrics despite significant fluctuations in sales and costs.

Are HCP Plastene latest results good or bad?

HCP Plastene's latest results show strong revenue growth with net sales up 57.22% quarter-on-quarter, but profitability is a concern as net profit declined slightly from the previous quarter and operating margins fell significantly. Investors should consider the impressive sales against the backdrop of declining margins and potential long-term sustainability challenges.

HCP Plastene's latest results present a mixed picture. On one hand, the company achieved impressive revenue growth, with net sales reaching ₹197.70 crores, marking a significant increase of 57.22% quarter-on-quarter and 68.86% year-on-year. This indicates strong market traction and business momentum.<BR><BR>However, the profitability aspect raises concerns. The consolidated net profit for the quarter was ₹3.96 crores, which, while up 164.00% year-on-year, declined by 1.25% compared to the previous quarter. Additionally, the operating margin fell sharply to 5.70%, down from 7.28% in the prior quarter, reflecting a contraction that suggests the company is sacrificing profitability to drive volume growth.<BR><BR>Overall, while the revenue growth is commendable, the declining margins and profitability indicate challenges that warrant careful consideration. Investors should weigh the strong sales performance against the backdrop of margin compression and elevated financial leverage, which could impact the company's long-term sustainability.

Has HCP Plastene declared dividend?

HCP Plastene has declared a 10% dividend, with an ex-date of November 14, 2025. Despite the dividend declaration, the dividend yield is 0%, and total returns have varied significantly across different time periods.

HCP Plastene has declared a 10% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 10%<BR>- Ex-date: 14 Nov 25<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the last 3 months, HCP Plastene experienced a price return of 6.48%, a dividend return of 0.56%, leading to a total return of 7.04%.<BR><BR>Over the 6-month period, the company saw an impressive price return of 81.68%, with a dividend return of 0.89%, resulting in a total return of 82.57%.<BR><BR>For the 1-year period, the price return was 16.13%, the dividend return was 0.59%, culminating in a total return of 16.72%.<BR><BR>In the 2-year period, HCP Plastene had a price return of -8.34%, a dividend return of 0.48%, which resulted in a total return of -7.86%.<BR><BR>Over the 3 years, the company faced a price return of -45.96%, with a dividend return of 0.29%, leading to a total return of -45.67%.<BR><BR>In the 4-year period, HCP Plastene recorded a price return of -75.43%, a dividend return of 0.15%, resulting in a total return of -75.28%.<BR><BR>Finally, over the 5-year period, the company achieved a remarkable price return of 3031.75%, with no dividend return, leading to a total return of 3031.75%.<BR><BR>Overall, HCP Plastene has declared a dividend, but the dividend yield remains at 0%. The total returns show significant variability, with strong performance over the 5-year period contrasted by negative returns in shorter time frames.

Should I buy, sell or hold HCP Plastene?

Which are the latest news on HCP Plastene?

Why is HCP Plastene falling/rising?

As of 03-Dec, HCP Plastene Bulkpack Ltd's stock price is rising, currently at 194.95, with a notable increase of 10.64% over the past week and 19.49% over the past month, significantly outperforming the Sensex. The company's strong financial health, including a 57.22% growth in net sales and high ROCE of 38.93%, supports this upward trend despite concerns about high debt levels.

As of 03-Dec, HCP Plastene Bulkpack Ltd's stock price is rising, currently at 194.95, reflecting a change of 1.4 (0.72%) upward. The stock has shown strong performance over various periods, with a notable increase of 10.64% over the past week and 19.49% over the past month, significantly outperforming the Sensex, which has declined by 0.59% in the same week and increased by only 1.34% in the past month. Year-to-date, the stock has risen by 27.42%, compared to the Sensex's 8.92% gain.<BR><BR>Today's performance indicates that the stock has outperformed its sector by 0.68% and has been on a consecutive gain for the last two days, accumulating a total return of 1.93% during this period. Furthermore, HCP Plastene is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, suggesting a positive trend in its price movement.<BR><BR>The company's financial health also supports the rising stock price, with a significant growth in net sales of 57.22% and positive results declared for the last six consecutive quarters. The return on capital employed (ROCE) is high at 38.93%, and the stock is trading at a discount compared to its peers, enhancing its attractiveness to investors. Additionally, there has been an increase in institutional investor participation, with a 4.43% rise in their stake, indicating confidence in the company's fundamentals.<BR><BR>Despite some concerns regarding high debt levels and poor long-term growth metrics, the current positive performance and strong financial results contribute to the stock's upward movement.